NCT04373824 is a NA clinical trial of Ivermectin in COVID, sponsored by Max Healthcare Insititute Limited.

Who is sponsoring NCT04373824?

NCT04373824 is sponsored by Max Healthcare Insititute Limited.

What drugs are being tested in NCT04373824?

Interventions in NCT04373824: Ivermectin.

Is NCT04373824 still recruiting?

NCT04373824 is currently status unknown. Last updated 4 May 2020.

Last reviewed 2020-05-04 · How we verify

NCT04373824

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study

Status unknown NA Last updated 4 May 2020

What this trial tests

NA trial testing Ivermectin in COVID in 50 participants. Status unknown.

Timeline

25 April 2020

Primary endpoint
25 July 2020

25 July 2020

Quick facts

Lead sponsor	Max Healthcare Insititute Limited
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	25 April 2020
Primary completion	25 July 2020
Estimated completion	25 July 2020
Sites	1 location across India

Drugs / interventions tested

Ivermectin (ivermectin) — full drug profile →

Conditions studied

COVID — all drugs for COVID →

Sponsor

Max Healthcare Insititute Limited

Who can join

Adults 18 to 75, any sex, with COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

At present, there are no specific treatments for COVID-19. WHO recommends four treatments for COVID 19 with drugs i.eRemdesivir, Lopinavir/ ritonavir, Lopinavir/ ritonavir with interferon beta -1a, and chloroquine or hydroxychloroquine. Currently, there are several ongoing clinical trials evaluating potential treatments. Recently, LeonCaly reported that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARSCoV-2 able to effect about 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrant further investigation for possible benefits in humans. The study rationale is to understand the effect of the drug on eradication of virus.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes.
Kaur H, Shekhar N, Sharma S, Sarma P, et al · · 2021 · cited 52× · PMID 33389725 · DOI 10.1007/s43440-020-00195-y
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
Jans DA, Wagstaff KM. · · 2020 · cited 52× · PMID 32942671 · DOI 10.3390/cells9092100
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
Formiga FR, Leblanc R, de Souza Rebouças J, Farias LP, et al · · 2021 · cited 48× · PMID 33038449 · DOI 10.1016/j.jconrel.2020.10.009
Ivermectin: potential candidate for the treatment of Covid 19.
Gupta D, Sahoo AK, Singh A. · · 2020 · cited 36× · PMID 32615072 · DOI 10.1016/j.bjid.2020.06.002
Ivermectin for preventing and treating COVID-19.
Popp M, Reis S, Schießer S, Hausinger RI, et al · · 2022 · cited 30× · PMID 35726131 · DOI 10.1002/14651858.cd015017.pub3
The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
Jans DA, Wagstaff KM. · · 2021 · cited 26× · PMID 33341233 · DOI 10.1016/j.bbrc.2020.10.042
COVID-19 associated complications and potential therapeutic targets.
Monpara JD, Sodha SJ, Gupta PK. · · 2020 · cited 21× · PMID 32926918 · DOI 10.1016/j.ejphar.2020.173548
Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic.
Bhandari R, Khanna G, Kuhad A. · · 2021 · cited 13× · PMID 33065092 · DOI 10.1016/j.ejphar.2020.173643

Verify or expand the search:

Other trials of Ivermectin

Trials testing the same drug.

NCT07396714 — the Efficacy of Ivermectin Alone or With Microneedling in Treatment of Cutaneous Warts. · EARLY_PHASE1 · not yet recruiting
NCT07145736 — Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical · Phase 4 · recruiting
NCT05605925 — Ivermectin-artemisinin Combination Therapy for Eradication of Malaria · Phase 4 · unknown
NCT05045937 — Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19 · unknown
NCT05643820 — Comparison of Oral Ivermectin and Permethrin 5% Lotion in Treatment of Pediculosis Capitis · Phase 1 · completed

Other recruiting trials for COVID

Currently open trials in the same condition.

NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting

Other Max Healthcare Insititute Limited trials

Trials by the same sponsor.

NCT07496333 — The Effect of Virtual Reality Distraction on Pain During Colonoscopy · NA · completed
NCT06456216 — Performance Evaluation of Diagnostic Accuracy of PanTum Detect Test for Detection of Solid Tumours in Known Cancer Popul · completed
NCT04422379 — COVID-19 and Liver Injury in Patients With or Without Underlying Liver Disease: A Multi-centre Retrospective-prospective · unknown
NCT04469660 — Impact of COVID-19 Pandemic on the Psychological Wellbeing of Healthcare Professionals in India · unknown
NCT04374487 — Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04373824 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Max Healthcare Insititute Limited
Last refreshed: 4 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04373824.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing